Switch View
© Globe Newswire
17.09.2025
ISIN: US6979471090
Palvella Therapeutics Inc
PVLA
LISTED
NASDAQ
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
News Preview
Recent advances in understanding venous malformation disease pathogenesis highlight the PI3K/AKT/mTOR pathway as a key driver of disease proliferation, spurring real-world off-label use of systemic rapamycin (sirolimus)...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US15713L1098
CervoMed Inc.
CRVO
LISTED
NASDAQ
CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
News Preview
BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that the promising development program and potential benefits of neflamapimod for the treatment of Dementia with Lewy Bodies (DLB) were h...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US00887A2042
Rein Therapeutics Inc
ALRN
LISTED
NASDAQ
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
News Preview
Peer-reviewed publication highlights potential breakthrough anti-fibrotic properties of LTI-03 in lung tissue from IPF patients...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
17.09.2025
ISIN: US00534A1025
Invivyd Inc
IVVD
LISTED
NASDAQ
Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
News Preview
NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company’s communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
17.09.2025
ISIN: US67080M1036
Nurix Therapeutics Inc
NRIX
LISTED
NASDAQ
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
News Preview
Presentation of preclinical data from novel IRAK4 protein degrader, GS-6791, discovered in Nurix's ongoing research collaboration with Gilead Sciences...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US82657M1053
Sight Sciences Inc
SGHT
LISTED
NASDAQ
Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use
News Preview
The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that favorable long-term safety and efficacy profiles make OMNI a beneficial treatment option for patients with primary open-angle glaucoma The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that f...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US5288723027
Lexicon Pharmaceuticals Inc
LXRX
LISTED
NASDAQ
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
News Preview
Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US05464T1043
Axsome Therapeutics Inc
AXSM
LISTED
NASDAQ
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
News Preview
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apnea Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apnea...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US98420X2027
X4 Pharmaceuticals Inc
XFOR
LISTED
NASDAQ
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
News Preview
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US89854M1018
TScan Therapeutics, Inc.
TCRX
LISTED
NASDAQ
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
News Preview
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025 Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: BMG762791017
Roivant Sciences Ltd
ROIV
LISTED
NASDAQ
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
News Preview
BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM)....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US7867001049
Sagimet Biosciences Inc
SGMT
LISTED
NASDAQ
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
News Preview
Denifanstat met all primary and secondary endpoints versus placebo...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
17.09.2025
ISIN: US5015751044
Kymera Therapeutics Inc
KYMR
LISTED
NASDAQ
Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses
News Preview
Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US14843C1053
Castle Biosciences Inc
CSTL
LISTED
NASDAQ
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
News Preview
Castle Biosciences has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek....
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: KR7196170005
Alteogen Inc
196170
LISTED
KOE
Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9)
News Preview
EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through its partner Qilu Pharmaceutical.DAEJEON, South Korea, Sept. 17, 2025 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Commission (EC) has granted marketing authorization for EYLUXVI® (code name:...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US15117B1035
Celldex Therapeutics, Inc.
CLDX
LISTED
NASDAQ
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
News Preview
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.09.2025
ISIN: US7389201077
Aspire Biopharma Holdings, Inc
ASBP
LISTED
NASDAQ
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
News Preview
BUZZ BOMB™ engages three specialized fitness influencers to grow the brandhttps://www.instagram.com/bobbymaximus/https://www.instagram.com/midwest_kong/https://www.instagram.com/ifbbpro_moose_the_stallion/The influencers have hundreds of thousands of followers across social platformsBUZZ BOMB's™ influencers known for their authenticity...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: SE0014855029
Implantica AG
IMP A-SDB
LISTED
STO
Implantica's RefluxStop® sparks strong excitement at the American Foregut Society meeting, ahead of pending US FDA approval
News Preview
VADUZ, Liechtenstein, Sept. 17, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces RefluxStop® was met with great enthusiasm and posi...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.09.2025
ISIN: US74366E1029
Protagonist Therapeutics Inc
PTGX
LISTED
NASDAQ
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
News Preview
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studiesIcotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD studyPreclinical proof-of-concept d...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US03969K1088
Arcutis Biotherapeutics Inc
ARQT
LISTED
NASDAQ
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
News Preview
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: DK0060027142
ALK-Abelló A/S
ALK B
LISTED
CPH
ALK and GenSci partner to expand the AIT market in China
News Preview
Inside Information...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: FR0010331421
Innate Pharma SA
IPH
LISTED
EURONEXT
Innate Pharma Reports First Half 2025 Business Update and Financial Results
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2025. The consolidated financial statements are attached to this press release.
“With key milestones anticipated over the next 12 months, our primary focus will be...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
News Preview
Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will support th...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: CH1335392721
Galderma Group AG
GALD
LISTED
XWSX
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin
News Preview
Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental factors on individuals with sensitive skin.1 Results from the study, conducted by dermatology experts from Galderma’s Global Sensitive Skincare Faculty (G...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Horus Pharma wird Zweitvermarktungspartner für Formycons Eylea®-Biosimilar FYB203 unter der Marke Baiama® in ausgewählten europäischen Ländern
News Preview
Pressemitteilung // 17. September 2025
Horus Pharma wird Zweitvermarktungspartner für Formycons Eylea®-Biosimilar FYB203 unter der Marke Baiama® in ausgewählten europäischen Ländern
Planegg-Martinsried – Die Formycon AG (FWB: FYB, „Formycon“) gibt bekannt, dass die Klinge Biopharma GmbH („Klinge“), Lizenznehmer und exklusiver Inhaber der weltwe......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
News Preview
Press Release // September 17, 2025
Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) announces that Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global co......
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US6876041087
Oruka Therapeutics, Inc.
ORKA
LISTED
NASDAQ
Oruka Therapeutics Announces $180 Million Private Placement
News Preview
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreemen...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: FR0000120578
Sanofi SA
SAN
LISTED
EURONEXT
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
News Preview
EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US6876041087
Oruka Therapeutics, Inc.
ORKA
LISTED
NASDAQ
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
News Preview
Half-life of approximately 100 days increases likelihood of once-per-year dosing...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private placement (the “offering”) to persons reasonably believed to be qualified instit...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.09.2025
ISIN: GB00BYX3WZ24
Hemogenyx Pharmaceuticals plc
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Third Patient Safety
News Preview
Third Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation LONDON, UNITED KINGDOM / ACCESS Newswire / September 17, 2025 / Hemogenyx Pharmaceuticals plc is pleased to announce that the third patient has been successfully treated in the ongoing Phase I clinical trial of HG-CT-1, the Company's proprietary Chimeric...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: CA22587M1068
Cresco Labs Inc
CL
LISTED
CSE
Cresco Labs Announces Voting Results of Its Annual General and Special Meeting of Shareholders
News Preview
Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the results of its annual general and special meeting of shareholders (the “Meeting”) held on September 16, 2025.
At the Meeting, the number of directors of the Company for the ensuing year was fixed at seven (7) and the following nominees for...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US29261A1007
Encompass Health Corp
EHC
LISTED
NYSE
Rosen Law Firm Encourages Encompass Health Corporation Investors to Inquire About Securities Class Action Investigation - EHC
News Preview
NEW YORK, Sept. 16, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Encompass Health Corporation (NYSE: EHC) result...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.09.2025
ISIN: US2498451085
Dermata Therapeutics Inc
DRMA
LISTED
NASDAQ
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
News Preview
- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne - SAN DIEGO, CA / ACCESS Newswire / September 17, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in der...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
ISIN: US78349D1072
Rxsight Inc
RXST
LISTED
NASDAQ
EXTENDED CLASS PERIOD: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against RxSight, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
News Preview
Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of RxSight, Inc. (NASDAQ: RXST) common stock between May 7, 2024 and July 8, 2025, inclusive (the “Class Period”). Captioned Gémesi v. RxSight, Inc., No. 25-cv-02093 (C.D. Cal.), the RxSight class action lawsuit charges RxSight a...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 16, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman
News Preview
REPL Investors with Losses Encouraged to Contact Hagens Berman
SAN FRANCISCO, Sept. 16, 2025 /PRNewswire/ -- A new securities class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and its executives. The lawsuit alleges that the company misled investors by overstating the success of its lead cancer drug, RP1, leading to...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
Nutex Health (NUTX) Faces Investor Lawsuit Over Alleged Revenue Inflation Scheme-- Hagens Berman
News Preview
SAN FRANCISCO, Sept. 16, 2025 /PRNewswire/ -- Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit that accuses the company of orchestrating a deceptive billing strategy to artificially boost its financial results. The litigation, filed...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
Lawsuit Targets Telehealth Firm LifeMD (LFMD) Over Alleged Misleading Statements -- Hagens Berman
News Preview
LFMD Investors with Losses Encouraged to Contact the Firm
SAN FRANCISCO, Sept. 16, 2025 /PRNewswire/ -- A new federal securities fraud class action lawsuit has been filed against LifeMD (NASDAQ: LFMD), alleging that the telehealth company and its executives provided investors with a misleading picture of its financial health and growth prospects....
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
ISIN: US5324571083
Eli Lilly and Co
LLY
LISTED
NYSE
Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
News Preview
The investigational once-daily oral pill led to an average weight loss of 27.3 lbs (12.4%) at the highest dose at week 72 in the Phase 3 study
Orforglipron demonstrated significant improvements across key cardiometabolic risk factors, supporting its potential as a treatment option for millions living with obesity
INDIANAPOLIS, Sept. 16, 2025 /PR...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 16, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
ISIN: JP3431300007
Nxera Pharma Co Ltd
45650
LISTED
XJPX
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
News Preview
Tokyo, Japan and Cambridge and London, UK, 17 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) and Cancer Research UK announce that the first patient has been dosed in a Phase 2a clinical trial (NCT05944237) evaluating Nxera’s investigational immunotherapy drug HTL0039732 (also known as NXE0039732) for advanced solid tum...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Rosen Law Firm Urges Savara Inc. (NASDAQ: SVRA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA), between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”). Savara is a clinical-stage biopharmaceutical company.
For more information, submit a for...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
NASDAQ: LFMD INVESTOR ALERT: Berger Montague Advises LifeMD, Inc. (NASDAQ: LFMD) Investors of an October 27, 2025 Deadline
News Preview
PHILADELPHIA, Sept. 16, 2025 /PRNewswire/ -- Berger Montague PC, national plaintiffs' law firm, announces a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025 (the "Class Period")....
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
ISIN: US86150R1077
Stoke Therapeutics Inc
STOK
LISTED
NASDAQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effe...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
ISIN: US29332G1022
Enhabit Inc
EHAB
LISTED
NYSE
Enhabit Announces Participation in Jefferies 2025 Healthcare Services Conference
News Preview
Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced its participation in the Jefferies 2025 Healthcare Services Conference.
Enhabit’s President and CEO Barb Jacobsmeyer and Chief Financial Officer Ryan Solomon will participate in a fireside chat on Tuesday, Sept. 30 at 10:55 a.m. CT. The fireside chat...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
ISIN: US64125C1099
Neurocrine Biosciences Inc
NBIX
LISTED
NASDAQ
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
News Preview
Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster AwardsSAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from the Phase 2 SAVITRI study of osavampator in ad...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
ISIN: US00857U1079
agilon health inc
AGL
LISTED
NYSE
agilon health to Participate in the 2025 Jefferies Healthcare Services Conference
News Preview
agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will participate in a fireside chat at the 2025 Jefferies Healthcare Services Conference on Tuesday, September 30 at 8:45am ET.
Interested investors and other parties may listen to a sim...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
ISIN: US74051N1028
Premier Inc
PINC
LISTED
NASDAQ
Premier Infusion and Healthcare Services, Inc. (Premier Infusion and HCS) Selects Premier, Inc. as Its GPO Partner to Power Ambulatory Infusion Growth
News Preview
Premier, Inc. (NASDAQ: PINC), a leading technology-enabled healthcare performance improvement company, today announced that it has entered a five-year group purchasing agreement with Premier Infusion and Healthcare Services, Inc. (Premier Infusion and HCS). Premier Infusion and HCS is a closed-door infusion pharmacy based in Torrance, California,...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
ISIN: IL0006290147
Teva Pharmaceutical Industries Ltd
TEVA
LISTED
TLV
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
News Preview
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California....
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Deadline Approaching: Savara Inc. (SVRA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”).
IF YOU ARE AN INVESTOR WHO SUFF...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
ISIN: US7611521078
Resmed Inc
RMD
LISTED
NYSE
Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025
News Preview
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, beginning at approximately 1:20 p.m. (British Summer Time)...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to p...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
ISIN: US50127T1097
Kura Oncology Inc
KURA
LISTED
NASDAQ
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
News Preview
Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs)...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages Lantheus Holdings, Inc. (LNTH) Investors To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (th...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
ISIN: US59503A2042
Microbot Medical Inc.
MBOT
LISTED
NASDAQ
Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
News Preview
$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options $25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potentia...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Carolina Complete Health and the Centene Foundation Award $1.3 Million Grant for Innovative Health Care Workforce Mental Health Program
News Preview
Multi-year initiative aims to combat clinician burnout and improve mental health support across North Carolina's healthcare workforce
DURHAM, N.C., Sept. 16, 2025 /PRNewswire/ -- The North Carolina Clinician and Physician Retention and Well-being (NCCPRW) Consortium announced today a transformative $1.3 million grant from the Centene Foundation,...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
ISIN: US10920G1004
Bright Green Corp
BGXX
LISTED
NASDAQ
PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation “BGXXQ” Q and A
News Preview
Fort Lauderdale, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PharmAGRI Capital Partners today announced its strategic focus on capturing a $10 billion total addressable market (TAM) in federal procurement of plant-based prescription drugs currently sourced from foreign manufacturers. This segment, while modest in size compared to the broader pharmaceu...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
ISIN: US03528H1095
Anixa Biosciences, Inc.
ANIX
LISTED
NASDAQ
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
News Preview
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] signaled the recent wave of regulatory momentum behind next-generation therapies. Meanwhile, advanced treatment platforms are achieving complete tumo...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
ISIN: US03528H1095
Anixa Biosciences, Inc.
ANIX
LISTED
NASDAQ
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
News Preview
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] signaled the recent wave of regulatory momentum behind next-generation therapies. Meanwhile, advanced treatment platforms are achieving complete tumo...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
